

Clinical Research Unit (CRU)

The Clinical Research Unit was established under the Department of Medical Oncology in 2020 with a grant of Rs.151.60 lakhs funded by the Biotechnology Industry Research Assistance Council (BIRAC) under the National Biopharma Mission. The unit is designed to support multidisciplinary, investigator-initiated research, conduct clinical trials, and maintain a comprehensive and diverse cancer registry.

Objective:


To advance cancer research through the ethical conduct of high-quality clinical trials and real-world data collection registry, contributing to improved patient care, scientific discovery, and national healthcare priorities.

Vision:

To be a nationally recognized center of excellence in clinical research—advancing patient care through innovation, collaboration, and the development of new treatment strategies, while contributing significantly to evidence-based oncology and public health in India.


Mission:

- To facilitate and execute scientifically rigorous and ethically compliant clinical trials, with a focus on oncology and hematology.
- To enhance institutional research capacity through training, state-of-the-art infrastructure, and multidisciplinary collaboration.
- To serve as a model site for government-funded cancer research programs and registries.
- To contribute to national cancer data systems through robust cancer registries and real-world data collection.




Summary of the projects at Clinical Research Unit

| Sl.No. | Project Name | Principal Investigator | Fund Granted | Study period |
|--------|--|--|---|--------------|
| 1. | NOCI-BIRAC Cancer Registry And Various Data Collection.(prospective cases) | Dr.Sunu Cyriac | Rs.151.60 lakhs | 2020-2025 |
| 2. | HCC Cancer registry for 5 main types of hematological cancers including (AML,ALL,APML,CML, MPN, MDS and lymphoma) | Dr. Sreeraj V | Funds the salary of registry staff | 2021-2026 |
| 3. | ICMR-HBCR Cancer registry for retrospective as well as prospective cancer cases. | Dr.Sunu Cyriac | Rs.3 lakhs | 2022- 2027 |
| 4. | ICMR funded Palliative Care Project | Dr.Sunu Cyriac | Total Budget of the Project for 6 sites Rs.1,11,98,054.4 | 2024-2026 |
| 5. | Metastatic colorectal cancer - Dr. Reddy Laboratory | Dr. Anilkumar Thazhatha Jose | Rs. 80,000 | 2024-2025 |
| 6. | RCT- Relapsed and Refractory Multiple Myeloma (A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD -264 and Darzalex ® in subjects with Relapsed and Refractory Multiple Myeloma) | Dr.Sunu Cyriac | NA | 2024-2026 |
| 7. | ICGA: Indian Cancer Genome ATLAS | Dr.Sunu Cyriac | | 2024-2029 |
| 8. | An Open Label Randomized Control Study to Assess the Impact of Integrated Onco- Geriatric Care on Reducing Chemotherapy Toxicities in Older Patients with Cancer. | Dr. Sunu Lazar Cyriac | IASCC Grant Amount Rs.1,00,000 | 2024-2025 |
| 9. | A Single-Center Observational Study Comparing 2023 FIGO Staging with 2009 FIGO Staging in Endometrial Cancer Patients: Implications for | Dr Rajkrishna B Dr Ashwin Oommen Philips | NA | 2025 |



| | | | | |
|-----|---|--|----|-----------------|
| | Treatment Planning and the Role of Molecular Testing | | | |
| 10. | Multicentric Evaluation of Comparative Assessment of Staging in Endometrial Cancer: FIGO 2009 vs. FIGO 2023 and the Role of Molecular Insights in Stratification Acronym (MECASIS) | Dr Ashwin Oommen Philips Dr. Rajkrishna B | NA | 2025 |
| 11. | Total Neoadjuvant Therapy in High-Risk Locally Advanced Rectal Cancer: A Multicentric Observational Study in the Indian Population (TIDE-R Study). | Dr. Febin Antony Dr. Ashwin Oommen Philips | NA | 2025 |
| 12. | A study on clinical profile of pure red cell aplasia following human erythropoitin treatment for anemia of chronic kidney disease treated with desidustal | Dr. Sreeraj V | NA | 2025-2026 |
| 13. | Comparative evaluation of consolidation strategies subsequent to azacytidine plus venetoclax- based induction in AML patients: A retrospective analysis of Haematological cancer consortium (HCC) registry in India | Dr. Sreeraj V | NA | 2025 (6 months) |
| 14. | Outcomes of adults \geq 40 years of age with newly diagnosed acute lymphoblastic leukemia ALL : A multicentre prospective registry analysis from haematology cancer consortium | Dr. Umnikrishnan | NA | 2025 (6 months) |
| 15. | A study to understand the practice patterns in high risk (MRD positive) and relapsed/refractory ALL | Dr. Sunu Lazar Cyriac | NA | 2025 (6 months) |
| 16. | Outcome of T cell non hodgkin Lymphoma from HCC registry | Dr. Sreeraj V | NA | 2025-2026 |
| 17. | Impact of consolidation radiotherapy in bulky Diffuse large B cell lymphoma by PET based response assessment | Dr. Sunu Lazar Cyriac | NA | 2025 (6 months) |



| | | | | |
|--|--|-----------------------|---------------------------------------|-----------|
| 18. | Post-operative intraperitoneal chemotherapy after interval cytoreduction in epithelial ovarian cancer (POICE 2024): multicenter, randomized, phase III trial | Dr. Anoj Kattukaran | NCG Project Total Fund : Rs.21,12,726 | 2024-2029 |
| Completed projects and Research Studies | | | | |
| 19. | Profile of Actionable oncogenic alterations (AGA) among patients with advanced NSCLC in South India- A multicentric study. | Dr. Sunu Lazar Cyriac | | |
| 20. | Phase 3- ABVD – Hodgkins lymphoma | Dr. Rennis Davis | | |



Betsy

Dr. BETSY THOMAS
MD, FRCOG, DNB, MICOG
PRINCIPAL
AMALA INSTITUTE OF MEDICAL SCIENCES
AMALA NAGAR, THRISSUR-680 555